Lannett Co Inc (NYSE:LCI) shares were up 0% during trading on Tuesday following a stronger than expected earnings report. The stock traded as high as $25.00 and last traded at $24.45. Approximately 2,148,912 shares were traded during trading, an increase of 119% from the average daily volume of 981,648 shares. The stock had previously closed at $24.45.

The company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.52 by $0.08. The business had revenue of $155.00 million during the quarter, compared to analyst estimates of $153.62 million. Lannett Co had a negative net margin of 0.09% and a positive return on equity of 19.80%. The company’s quarterly revenue was down 4.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.77 EPS.

A number of equities research analysts have issued reports on the company. Deutsche Bank AG reiterated a “hold” rating and issued a $23.00 price target (up previously from $22.00) on shares of Lannett Co in a research note on Monday, July 17th. Roth Capital set a $27.00 price objective on shares of Lannett Co and gave the company a “buy” rating in a report on Tuesday, August 22nd. ValuEngine downgraded shares of Lannett Co from a “buy” rating to a “hold” rating in a report on Friday, September 1st. BidaskClub downgraded shares of Lannett Co from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Finally, Zacks Investment Research raised shares of Lannett Co from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a report on Tuesday, July 18th. One analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company. Lannett Co has a consensus rating of “Hold” and a consensus target price of $21.80.

Several large investors have recently bought and sold shares of the company. BlackRock Inc. lifted its position in Lannett Co by 52,610.9% during the first quarter. BlackRock Inc. now owns 3,903,766 shares of the company’s stock valued at $87,250,000 after purchasing an additional 3,896,360 shares during the period. Vanguard Group Inc. increased its stake in shares of Lannett Co by 6.2% during the second quarter. Vanguard Group Inc. now owns 2,901,885 shares of the company’s stock worth $59,198,000 after purchasing an additional 168,454 shares in the last quarter. State Street Corp increased its stake in shares of Lannett Co by 7.9% during the first quarter. State Street Corp now owns 1,279,860 shares of the company’s stock worth $28,606,000 after purchasing an additional 93,186 shares in the last quarter. Russell Investments Group Ltd. increased its stake in shares of Lannett Co by 27.0% during the third quarter. Russell Investments Group Ltd. now owns 669,298 shares of the company’s stock worth $12,349,000 after purchasing an additional 142,278 shares in the last quarter. Finally, Heartland Advisors Inc. increased its stake in shares of Lannett Co by 20.0% during the second quarter. Heartland Advisors Inc. now owns 600,000 shares of the company’s stock worth $12,240,000 after purchasing an additional 100,000 shares in the last quarter. Institutional investors and hedge funds own 87.67% of the company’s stock.

The stock has a market capitalization of $790.43, a PE ratio of 7.24, a price-to-earnings-growth ratio of 1.95 and a beta of 2.73. The company has a quick ratio of 2.09, a current ratio of 2.72 and a debt-to-equity ratio of 1.50.

COPYRIGHT VIOLATION WARNING: “Lannett Co Inc (LCI) Trading Up 0% After Earnings Beat” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/11/08/lannett-co-inc-lci-trading-up-0-after-earnings-beat.html.

Lannett Co Company Profile

Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.

Receive News & Ratings for Lannett Co Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett Co Inc and related companies with MarketBeat.com's FREE daily email newsletter.